NutriSystem (NTRI) Shares Down 10% on Disappointing Results; One Firm Initiates Coverage, Two Downgrade
Tweet
Share
E-mailGet Alerts NTRI Hot Sheet
Price: $42.89 --0%
Rating Summary:
0 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
0 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Shares of NutriSystem (Nasdaq: NTRI) are trading down over 10%, but off session lows. Last night, the Company reported a Q4 loss of $0.04 per share, 2 cents worse than consensus estimates. However, revenues topped estimates by about $2.5 million ($66.9m vs $64.43m).
Overall, the Q4 report was disappointing, given the decline in numbers year-over-year. Q4'10 EPS was $0.25 and revenues were about $88 million.
Adding to investors dismay, NTRI guided below estimates, seeing a Q1 loss between $0.05-0.10 vs. current estimates of $0.10 profit. NutriSystem also cut FY12 EPS guidance to between $0.45-0.55 per share vs. the consensus of $0.92.
On March 1, 2012, Auriga reiterated a 'Buy' rating, but expected a weak overall quarter, and expected more focus on 2012. However, this morning, Auriga downgraded shares from Buy to Hold, slashing its price target from $17 to $11. The firm also dropped FY12 EPS to $0.51 from $1.11 and FY13 EPS to $0.71 from $1.23.
Also this morning, Avondale Partners downgraded NTRI from Outperform to Market Perform, cutting its price target down to $9.50 from $18.
Standpoint Research analyst, Ronnie Moas, however, saw something different is shares of NTRI, and initiated coverage on the stock with a 'Buy' rating about six hours before the company reported its dismal results. (Time to dollar-cost average)
Shares of NTRI did tap a new 52-wk low of $10.41 vs. previous range $10.46 - 16.11. However, the company reaffirmed its quarterly cash dividend (annualized at about 6%) and does expect to be profitable for full-year 2012, so today's dip may indeed may be a longer-term opportunity. Currently, NTRI's market cap is $288 mln vs. Weight Watchers (NYSE: WTW), which is $5.71 billion.
To see more ratings on NTRI, Click Here
Overall, the Q4 report was disappointing, given the decline in numbers year-over-year. Q4'10 EPS was $0.25 and revenues were about $88 million.
Adding to investors dismay, NTRI guided below estimates, seeing a Q1 loss between $0.05-0.10 vs. current estimates of $0.10 profit. NutriSystem also cut FY12 EPS guidance to between $0.45-0.55 per share vs. the consensus of $0.92.
On March 1, 2012, Auriga reiterated a 'Buy' rating, but expected a weak overall quarter, and expected more focus on 2012. However, this morning, Auriga downgraded shares from Buy to Hold, slashing its price target from $17 to $11. The firm also dropped FY12 EPS to $0.51 from $1.11 and FY13 EPS to $0.71 from $1.23.
Also this morning, Avondale Partners downgraded NTRI from Outperform to Market Perform, cutting its price target down to $9.50 from $18.
Standpoint Research analyst, Ronnie Moas, however, saw something different is shares of NTRI, and initiated coverage on the stock with a 'Buy' rating about six hours before the company reported its dismal results. (Time to dollar-cost average)
Shares of NTRI did tap a new 52-wk low of $10.41 vs. previous range $10.46 - 16.11. However, the company reaffirmed its quarterly cash dividend (annualized at about 6%) and does expect to be profitable for full-year 2012, so today's dip may indeed may be a longer-term opportunity. Currently, NTRI's market cap is $288 mln vs. Weight Watchers (NYSE: WTW), which is $5.71 billion.
To see more ratings on NTRI, Click Here
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DA Davidson Starts Everus (ECG) at Buy
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Rockwell Automation (ROK) PT Lowered to $490 at DA Davidson
Create E-mail Alert Related Categories
Analyst Comments, Downgrades, Earnings, Guidance, New CoverageRelated Entities
Avondale Partners, Dividend, Standpoint Research, AurigaSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
